yahoo_financeOriginal article
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
NDA FilingJoenjaPositive
AI Analysis
Summary
Pharming announced that the U.S. FDA has accepted and granted Priority Review status to a supplemental NDA for lower doses of Joenja to treat children with APDS.
Outcome Details
FDA acceptance and Priority Review of supplemental NDA for lower doses
Importance:7/10
Sentiment:
0.70
FDA approvalPriority ReviewpediatricJoenjaAPDSsNDA
Related Companies
Read the original article
Published by yahoo_finance on September 25, 2026 2:30 PM